Research and Markets: Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2015
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.
We look at how a biotech ETF holds up in an iffy climate for those stocks.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
Health-care stocks are on a tear as demand slowly returns.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
Three ways to separate long-term winners from stocks that fizzle.